Dengue Vaccines Market Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
To enhance tetravalent
protection, sequential immunisation in addition to a heterologous prime-boost
approach is gaining popularity. Companies operating in the global dengue
vaccine market are likely to collaborate with scientists at organisations like
the Singapore-MIT Alliance for Research and Technology (SMART), who are seizing
the chance to make sequential vaccination safer and more effective than the
current tetravalent vaccine.
One of the most crucial
strategies for getting a competitive edge in the market for dengue vaccines
globally is investing in vaccine R&D. There is a good chance that
continuing research will assist in the creation of next-generation vaccines for
TB, dengue, and malaria. Over the forecast period, rising dengue prevalence is
anticipated to fuel dengue
vaccines market expansion. For instance, between epidemiological week 1
and epidemiological week 22 of 2019, the Pan American Health Organization
reported a total of 1,191,815 cases of dengue, of which 546,589 were
laboratory-confirmed and 5,599 were categorised as severe dengue.
Additionally, research and
development of live attenuated vaccines is anticipated to support market
expansion. For instance, Dengvaxia was licenced by the U.S. FDA in May 2019 to
prevent dengue infection brought on by any serotype of the dengue virus. It is
a chimaera vaccine that is live attenuated, tetravalent, and created using
recombinant DNA.
Comments
Post a Comment